Bambang Tiksnadi1, Herry Herman1. 1. Department of Orthopaedic Surgery and Traumatology, Padjadjaran State University, Bandung, Indonesia.
Abstract
UNLABELLED: In the present study, we analysed the association between the incidence of tuberculous spondylitis with the Natural Resistance Associated Macrophage Protein 1 (NRAMP1, also known as Solute Carrier Family 11a member1) polymorphism by studying the genetic segregation of this polymorphism and the incidence of the disease among members of the West Javanese population undergoing surgery for tuberculous spondylitis at our institution. We compared the distribution of NRAMP1 polymorphism at two specific sites, namely D543N, and 3'UTR, among subjects with pulmonary tuberculosis and tuberculous spondylitis. We found no significant differences in distribution of polymorphism between the two groups, or between pulmonary tuberculosis and tuberculous spondylitis compared to healthy subjects. However, a pattern emerged in that polymorphisms at the two sites seemed to be protective against development of tuberculous spondylitis in our study population. We concluded that in the West Javanese population, there is no association between NRAMP1 polymorphism with the propensity for development of pulmonary tuberculosis or tuberculous spondylitis. In fact, NRAMP1 may provide protection against the development of tuberculous spondylitis. KEY WORDS: tuberculous spondylitis, NRAMP1, polymorphism.
UNLABELLED: In the present study, we analysed the association between the incidence of tuberculous spondylitis with the Natural Resistance Associated Macrophage Protein 1 (NRAMP1, also known as Solute Carrier Family 11a member1) polymorphism by studying the genetic segregation of this polymorphism and the incidence of the disease among members of the West Javanese population undergoing surgery for tuberculous spondylitis at our institution. We compared the distribution of NRAMP1 polymorphism at two specific sites, namely D543N, and 3'UTR, among subjects with pulmonary tuberculosis and tuberculous spondylitis. We found no significant differences in distribution of polymorphism between the two groups, or between pulmonary tuberculosis and tuberculous spondylitis compared to healthy subjects. However, a pattern emerged in that polymorphisms at the two sites seemed to be protective against development of tuberculous spondylitis in our study population. We concluded that in the West Javanese population, there is no association between NRAMP1 polymorphism with the propensity for development of pulmonary tuberculosis or tuberculous spondylitis. In fact, NRAMP1 may provide protection against the development of tuberculous spondylitis. KEY WORDS: tuberculous spondylitis, NRAMP1, polymorphism.
Tuberculous infection (TB) may result in pulmonary or
extrapulmonary complications. One of the more devastating
extrapulmonary manifestations is tuberculous spondylitis
(STB). At least half of tuberculous musculoskeletal
infections eventually present as spondylitis. At our
institution STB accounts for 40% of all patients requiring
surgery for back problems. Among the most intriguing
questions are what factors affect the natural course of the
infection, whether it will first present as pulmonary
tuberculosis (PTB), or as STB or as both at the same time.Among the many types of Gell and Coombs hypersensitivity
reactions, immunity against TB is mediated by delayed hypersensitivity. Since TB bacteria are intracellular, it takes
some time for the individuals’ immune system to form
immunity. Clearance of intracellular parasites is not
mediated by an adaptive response, since mycobacterium
antigens aren’t at the infected cell surface; instead, immunity
arises in the form of macrophage aggregation under the
influence of T-helper type 1 (Th1) cytokines, which in turn
drive cellular responses. This results in walling-off of the
infections by macrophages and monocytes cells as
granulomas. Clearance of intracellular parasites is achieved
by lysis of the infected cells and bacteria through the
oxygen-dependent and oxygen-independent mechanisms.
Among these mechanisms are the nitric oxide (NO) system
that generates oxygen radicals and lysozymes in
phagolysosomes that disintegrate parasites. Both of these
mechanisms depend upon the transport of soluble factors
such as Mn2+ and Fe2+ acting as reaction cofactors and acidity
(pH) regulators1. One of the proteins facilitating such
transport in macrophages, Natural Resistance Associated
Macrophage Protein 1 (NRAMP1), is widely studied for its
effect on TB outcomes. Due to its function in regulating
influx of soluble factors it also is known by an alternate
name, Solute Carrier Family 11a member1.In an initial study in a West African population by Bellamy
et. al., polymorphisms were identified at the 3’UTR, D543N,
INT4 and 5’CA sites of the gene that correspond with
susceptibility to PTB 2. Further genetics studies validated
these results in closely related African regions2-5, but on the
other hand, subsequent studies in Asian populations varied6-10,
validated those results only at only certain sites, mostly at
d543 and 3’UTR11,12. Several other studies including one in
Sulawesi showed no correlation between polymorphism at
NRAMP1 with susceptibility to PTB13. Results of animal
experiments investigating the role of NRAMP1 in resistance
to TB infection were inconsistent14.Studies about the association between NRAMP1
polymorphism and extrapulmonary manifestation are
limited, and most concentrated only on pleural
manifestations15. A particular study about STB in India16
reported no significant association between NRAMP1
polymorphisms and STB. However, they did found increased
polymorphisms at 3’UTR and D543N in STB.The above results are intriguing; thus we sought to produce
data on patients at our institution undergoing surgery for
STB. Advances in knowledge about the polymorphism that
are associated with STB may contribute improved
identification of susceptible individuals and lead to
improvements disease control and prevention in the future.
Materials and Methods
The study sample consisted of patients who underwent
surgery for STB for various indications between January
2003 and August 2008, and also included pulmonary TBpatients and healthy study participants as controls.Polymorphism at D543N and 3' UTR sites were identified
using published primers and the restriction fragment length
polymorphism (RFLP) method. Briefly, DNA was prepared
from blood utilizing a high purity polymerase chain reaction
(PCR) template preparation kit (Boehringer Mannheim,
Mannheim, Germany); we used PCR and PCR RFLP utilized
primers: F 5’-gca tct ccc caa ttc atg gt-3’ and R 5’ aac-tgtccc-
act-cta-tcc-tg 3’ for D543N and F 5’gca-tct-ccc-caa-ttcatg-
gt 3’ and R 5’tgt- ccc-act cta-tcc-tg-3’ for 3’UTR
polymorphism (Bbioneer Kaist, Taejon, Republic of Korea).
AvaII restriction was used to differentiate between D543N
polymorphisms (Figure 1), and FokI was utilized to
differentiate between 5’UTR polymorphisms (Figure 2). The
distribution of polymorphisms at both sites was compared in
STB and PTB participants and between STB and healthy
participants. Chi square analysis was used to assess
statistical differences between the distributions of
polymorphisms utilizing commercial statistical analysis
package SPSS version 10 for Windows (SPSS Inc., Chicago,
Il, USA).
Figure 1
: PRepresentative RFLP (restriction fragment length
polymorphism) profile of D543N with AvaII restriction.
Lane 1, molecular size marker; lane 2, undigested
product; lane 3,4,6,7,8 digested PCR fragments of 126
pb, 79 pb, 39 pb representing genotype GG, lane 5
digested PCR fragment of 201 pb, 126 pb, 79 pb, and 39
pb representing genotype GA.
Figure 2
: Representative RFLP (restriction fragment length
polymorphism) profile of 3’UTR with FokI restriction.
Lane1,molecular weight marker 50; lane 2, undigested
PCR product; lane 4,5,7,8,9,10 digested PCR fragments of
211 and 33 pb representing TGTG+/TGTG+ genotype.
Lane 6,11,13 digested PCR fragment of 244 pb (not
fragmented) representing TGTG-/TGTG-genotype. Lane
12,14. Digested pcr fragments of 244 pb,211 pb, and 33
pb representing TGTG+/TGTG- genotype.
The ethics committee of the Hasan Sadikin Hospital
approved the study protocol and the study was conducted in
accordance with the Helsinki Declaration (1975).
Results & Discussion
Forty-one STBpatients (26 (63.4%) females and 15 (36.6%)
males) of West Javanese descent domiciled in and around the
city of Bandung (71.4%) as well as from various outlying
area were recruited for this study (Table I; mean age, 35.9 ±
11.3 y (range, 15- 66 y. Ninety per cent of these patients had
back pain, 76% had gibbus, and 54% had neurological
deficit. One hundred sixty four patients with Pulmonary
Tuberculosis and 123 healthy subjects were included as
controls resulting in a total of 328 study participants (Table I).
Table I
: Distribution of study populations
We found no significant differences in polymorphism
distribution between STB and PTB at D543N (p=0.56) or at
3’UTR (p=0.40) (Table II). We therefore believe that the
polymorphisms have no decisive role in determining the
natural outcomes of TB infection (i.e., PTB or STB). This
result is more aligned with recent studies on Asian
population, showing that putative race and ethnic
background supercede the influence of NRAMP1 on TB
outcomes.
Table II
: Distribution of D543N and 3’UTR polymorphism between STB, TBP, and normal control. The haploid distribution of
the G allele of D543N were 82.9% : 80.5% : 81.7%, for STB, PTB and normal, while the distribution of a allele were 17.1% :
19.5% : 18.3% respectively. The distribution of G and A allele did not differ between STB-TBP and normal control (p = 0.346).
The diploid distributions of D543N in the sequence of G/G : G/A : A/A were 68.3% : 29.3% : 2.4% for STB , 63.4% : 34.2% :
2.4% for PTB, and 69.1% : 25.2% : 5.7% for normal control.
OR: Odds Ratio, STB: Tuberculous Spondylitis, PTB: Pulmonary Tuberculosis
Further, we found no significant differences in
polymorphism distribution between STB and healthy
subjects, either at D543N (p=0.92) nor at 3’UTR (p=0.92)
(Table II), leading us to believe that that the polymorphism
does not have a role in increased susceptibility to STB in our
population. This finding was similar to results reported by
Selvaraj et al.16Since about half of the study population in the STB group
also had PTB, we attempted to investigate the role of the
NRAMP1 polymorphism in increasing susceptibility of PTB
patients to STB. To do so, we compared the polymorphism
distribution in the PTB only group to the STB+PTB group.
Although, we found no significant distribution differences at
D543N (p=0.295) or at 3’UTR (p=0.234) (Table III), there
were increasing polymorphisms at both sites in subjects with
PTB only, compared to subjects with STB+PTB, perhaps
indicating that the polymorphism is instead associated with
protection against STB for PTB patients. This result
contradicts the results of in India by Selvaraj et. al.16
querying the same sites. Possible explanations may lie in the
fact that our study compared the polymorphism distribution
differences between cases of PTB and PTB + STB, while the
study in India compared STB to normal healthy controls.
Taken together, however, the results point to an effect on the
propensity for development of STB. Definitive answers lie in
a future, larger epidemiological study.
Table III
: Distribution of polymorphic subjects in PTB group compared to PTB + STB at the D543N from GG to GG and AA and
AT 3’ UTR from TGTG +/+ to TGTG +/- and TGTG -/-.
: Distribution of study populations: Distribution of D543N and 3’UTR polymorphism between STB, TBP, and normal control. The haploid distribution of
the G allele of D543N were 82.9% : 80.5% : 81.7%, for STB, PTB and normal, while the distribution of a allele were 17.1% :
19.5% : 18.3% respectively. The distribution of G and A allele did not differ between STB-TBP and normal control (p = 0.346).
The diploid distributions of D543N in the sequence of G/G : G/A : A/A were 68.3% : 29.3% : 2.4% for STB , 63.4% : 34.2% :
2.4% for PTB, and 69.1% : 25.2% : 5.7% for normal control.
OR: Odds Ratio, STB: Tuberculous Spondylitis, PTB: Pulmonary Tuberculosis: Distribution of polymorphic subjects in PTB group compared to PTB + STB at the D543N from GG to GG and AA and
AT 3’ UTR from TGTG +/+ to TGTG +/- and TGTG -/-.: PRepresentative RFLP (restriction fragment length
polymorphism) profile of D543N with AvaII restriction.
Lane 1, molecular size marker; lane 2, undigested
product; lane 3,4,6,7,8 digested PCR fragments of 126
pb, 79 pb, 39 pb representing genotype GG, lane 5
digested PCR fragment of 201 pb, 126 pb, 79 pb, and 39
pb representing genotype GA.: Representative RFLP (restriction fragment length
polymorphism) profile of 3’UTR with FokI restriction.
Lane1,molecular weight marker 50; lane 2, undigested
PCR product; lane 4,5,7,8,9,10 digested PCR fragments of
211 and 33 pb representing TGTG+/TGTG+ genotype.
Lane 6,11,13 digested PCR fragment of 244 pb (not
fragmented) representing TGTG-/TGTG-genotype. Lane
12,14. Digested pcr fragments of 244 pb,211 pb, and 33
pb representing TGTG+/TGTG- genotype.
Conclusion
We conclude that in West Javanese patients undergoing
surgery for STB in our institution, there were no associations
between NRAMP1 polymorphisms at D543N and 3’UTR
sites and susceptibility to development of STB, PTB or
STB+ PTB. Of note, within the PTB group, we found that
polymorphisms provide a certain level of protection against
development of STB+ PTB. Further study with a larger
sample is warranted to produce a statistically relevant
observation.
Authors: Hong-fei Duan; Xin-hua Zhou; Yu Ma; Chuan-you Li; Xiao-you Chen; Wei-wei Gao; Su-hua Zheng Journal: Zhonghua Jie He He Hu Xi Za Zhi Date: 2003-05
Authors: E G Hoal; L A Lewis; S E Jamieson; F Tanzer; M Rossouw; T Victor; R Hillerman; N Beyers; J M Blackwell; P D Van Helden Journal: Int J Tuberc Lung Dis Date: 2004-12 Impact factor: 2.373
Authors: Y S Liaw; J J Tsai-Wu; C H Wu; C C Hung; C N Lee; P C Yang; K T Luh; S H Kuo Journal: Int J Tuberc Lung Dis Date: 2002-05 Impact factor: 2.373
Authors: W Liu; W C Cao; C Y Zhang; L Tian; X M Wu; J D F Habbema; Q M Zhao; P H Zhang; Z T Xin; C Z Li; H Yang Journal: Int J Tuberc Lung Dis Date: 2004-04 Impact factor: 2.373